REFERNCES

1. **Aase JM(1990).** *Diagnostic Dysmorphology.* 3rd ed. New York, NY: Plenum Medical Book Co; 32 –34.
2. **Accardo PJ , Capute AJ (1994).** Mental Retardation. In: F Oski, CD DeAngelis and RD Feigin *et al.*, Editors, *Principles and Practice of Pediatrics,* Lippincott, Philadelphia pp. 673–679.
3. **Albertson DG, Pinkel D(2003).** Genomic micro arrays in human genetic disease and cancer. *Hum Mol Genet.* 12 (spec No. 2):R145–R152.
4. **Alexander K.C. Leung, M.B.B.S (1999).** Alberta Children's Hospital and University of Calgary, Alberta, Canada.
5. **Al-Qudah AA (1998).** Screening for congenital hypothyroidism in cognitively **delay**ed children. *Ann Trop Pediatr* . 18: 285–288.
6. **American Academy of Pediatrics, Committee on Committee on Children With Disabilities(2006).** Developmental surveillance and screening of infants and young children. Pediatrics 108 :192.
7. **American Academy of Pediatrics Committee on Children with Disabilities(2001).** Developmental surveillance and screening in infants and young children. *Pediatrics* . 108: 192–196.
8. **American Psychiatric Association (2000).** Diagnostic and statistical manual of mental disorders, text revision, 4th ed. Washington: American Psychiatric Association ; 41–49.
9. **Amir N .; El-Peleg O.; Shalev, R. S.; et al(1987) :** Glutaric aciduria type I: clinical heterogeneity and neuroradiologic features. *Neurology* 37: 1654-1657.
10. **Ankaran S, Laptook AR, Ehrenkranz RA, *et al* (2005).** "Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy". *N. Engl. J. Med.* **353** (15): 1574–84.

11. **Ashwal S, Russman BS, Blasco PA, *et al* (2004).** "Practice parameter: diagnostic assessment of the child with cerebral palsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society". *Neurology* **62** (6): 851–63**.**
12. **Asku F(1990).** Nature and prognosis of seizures in patients with cerebral palsy. Dev Med Child Neurol 32:661–668.
13. **Bachman JA, Bachman WG, Franzel AS, et al (1994)** Preteaching developmentally delayed preschoolers to aid vision screening. Optom Vis Sci . 71: 713–716.
14. **Bacino CA, Kashork CD, Davino NA, et al (2000)** Detection of a cryptic translocation in a family with mental retardation using FISH and telomere region-specific probes. *Am J Med Genet.* ;92 :250 –255.
15. **Balaban B, Yasar E, Dal U, et al (2007).** "The effect of hinged ankle-foot orthosis on gait and energy expenditure in spastic hemiplegic cerebral palsy". *Disability and rehabilitation* **29** (2): 139–44.
16. **Banatvala JE, Brown DW(2004);** Rubella.; Lancet 3;363(9415):1127-37.
17. **Battaglia A, Bianchini E, Carey JC (1999).** Diagnostic yield of the comprehensive assessment of developmental delay/mental retardation in an institute of child neuropsychiatry. *Am J Med Genet* . 82: 60–66.
18. **Bennett FC, Guralnick MJ(1991).** Effectiveness of developmental intervention in the first five years of life. Pediatr Clin North Am 38:1513-1528.
19. **Berrueta-Clement JR, Schweinhard L, Barnett W, et al (1984).** Changed lives: the effects of the Perry preschool program on

youths through age 19. No. 8 of Monographs of the High/Scope Educational Research Foundation. Ypsilanti, Mich.: High/Scope Press.

20. **Beukelman, David R.; Mirenda (1999).** Augmentative and Alternative Communication: Management of severe communication disorders in children and adults. Pat (2 ed.). Baltimore: Paul H Brookes Publishing Co. pp. 246–249.
21. **Biesecker LG(2002).** The end of the beginning of chromosome ends. *Am J Med Genet.* 107 :263 –266.
22. **Blackman JA (1991).** Neonatal intensive care: is it worth it? Developmental sequelae of very low birthweight. Pediatr Clin North Am 38:1497-1511 .
23. **Blasco PA.(1991)** Pitfalls in developmental diagnosis. Pediatr Clin North Am 38:1425-1438.
24. **Bouhadiba Z, Dacher J, Monroc M, et al(2000).** MRI of the brain in the evaluation of children with **developmental delay**. J Radiol . 81: 870–873.
25. **Brandt, N. J.; Brandt, S.; Christensen, et al(1978) :** Glutaric aciduria in progressive choreo-athetosis. *Clin. Genet.* 13: 77-80.
26. **Cakmak A, Zeyrek D, Cekin A, Karazeybek H (2008).** Dandy-Walker syndrome together with occipital encephalocele. *Minerva Pediatr*. 60(4):465-8.
27. **Camfield CS, Camfield PR, Wirrell E, et al(1996).** Incidence of epilepsy in childhood and adolescents: a population based study in Nova Scotia from 1977–1985. Epilepsia 37:19–23.

28 Capute and Accardo's(2005). Neurodevelopmental.28 Disabilities in Infancy and Childhood, *Third* edition.

29. **Capute AJ, Accardo PJ(1996).** A neurodevelopmental perspective on the continuum of developmental disabilities. In: Capute AJ, Accardo PJ, eds. *Developmental Disabilities in Infancy and Childhood* 2nd ed. Vol 1. Baltimore, MD: Paul H. Brookes; 1 –22

30. **Centeno RS, Winter J, Bentson JR, et al (1983):** CT evaluation of Haemophilus influenzae meningitis with clinical and pathologic correlation. Comput Radiol 7(4):243-249.

31. **Chelly, J., & Mandel, J (2001).** L. Monogenic causes of X-linked mental retardation. *Nature Reviews Genetics* **2**, 669–679 .

32. **Chow SL, Rohan C, Morris AA. (2003).** "Rhabdomyolysis in glutaric aciduria type I.". *J Inherit Metab Dis.* **26** (7): 711–2.

33. **Coplan J. ELM Scale(1983)** (Early Language Milestone Scale). Tulsa, Okla.: Modern Educational Corporation.

34. **Couvert P, Bienvenu T, Aquaviva C, et al (2001).** MECP2 is highly mutated in X-linked mental retardation. *Hum Mol Genet.* 10 :941 –946

35. Craigen, W. J.(1996) : Leigh disease with deficiency of lipoamide dehydrogenase: treatment failure with dichloroacetate. Pediat. Neurol. 14: 69-71.

36. **Crawford DC, Acuna JM, Sherman SL(2001).** FMR1 and the fragile X syndrome: human genome epidemiology review. *Genet Med* .3: 359–371.

37. **Curatolo P, Arpino C, Stazi MA, et al (1995).** Risk factors for the co-occurrence of partial epilepsy, cerebral palsy and mental retardation. Dev Med Child Neurol 37:776–782.

38. **Curry CJ, Stevenson RE, Aughton D, et al (1997).** Evaluation of mental retardation: recommendations of a consensus conference—

American College of Medical Genetics. Am J Med Genet. 72 :468 –477.

39. **Dart, Hurlbut, Boyer-Hassen (2004)** pp. 1Timbrell, J.A., ed . "Biochemical mechanisms of toxicity: Specific examples". Principles of Biochemical Toxicology, 4th edition. Informa Health Care.
40. **Demaerel P, Kingsley DP, Kendall BE(1993).** Isolated neurodevelopmental delay in childhood: clinicoradiological correlation in 170 patients. *Pediatr Radiol* . 23: 29–33.
41. **Di Mario S, Basevi V, Gagliotti C, et al(2009);** Prenatal education for congenital toxoplasmosis.Cochrane Database Syst Rev 21;(1):CD006171.
42. **Dionisi-Vici C, Deodato F, Raschinger W, et al (2006).** "Classical organic acidurias, propionic aciduria, methylmalonic aciduria, and isovaleric aciduria: long-term outcome and effects of expanded newborn screening using tandem mass spectrometry". J Inherit Metab Dis. 29 (2-3): 383–389.
43. **Dobos AEJ, Dworkin PH, Bernstein BA (1994).** Pediatricians' approaches to developmental problems: has the gap been narrowed? Dev Behav Pediatr . 15: 34–38
44. **Dworkin PH (1989).** British and American recommendations for developmental monitoring: the role of surveillance. Pediatrics 84:1000-1010.
45. **Fenichel GM (2001).** Psychomotor retardation and regression. In: Clinical pediatric neurology: a signs and symptoms approach, 4th ed. Philadelphia: WB Saunders, 117–147.
46. **Filiano JJ, Bellimer SG, Kunz PL(2002).** Tandem mass spectrometry and newborn screening: pilot data and review. Pediatr Neurol. 26 :201 –204

47. **First LR, Palfrey JS(1994).** The infant or young child with developmental delay. N Engl J Med . 330: 478–483

48. **Folsom RC, Diefendorf AO (1999).** Physiologic and behavioral approaches to pediatric hearing assessment. *Pediatr Clin North Am* . 46: 107–120.

49. **Franceschetti S, Antozzi C, Binelli S, et al(1993).** Progressive myoclonus epilepsies: an electroclinical, biochemical, morphological and molecular genetic study of 17 cases. *Acta Neurol Scand* . 87: 219–223.

50. **Frankenburg WC, Dodds J, Archer P, et al (1992)** The Denver II: a major revision and restandardization of the Denver Developmental Screening Test. Pediatrics. 89 :91 –97.

51. **Frankenburg, W.K. and Dodds, J.B(1967).** The Denver Developmental Screening Test. J. Pediat., 71:181.

52. **Frankenburg, W.K., Dodds, J., Archer, P. et al(1992).** The DENVER II: A major revision and restandardization of the Denver Developmental Screening Test. Pediatrics, 89:91-97, 1992

53. **Frankenburg, William K. (2002).** "Developmental Surveillance and Screening of Infants and Young Children". *Pediatrics* **109** (109): 144–145.

54. **Gabrielli O, Salvolini U, Coppa GV, et al (1990).** Magnetic resonance imaging in the malformative syndromes with mental retardation. Pediatr Radiol. 21 :16 –19

55. **Ghalli I et al.(2002).** Egyptian growth curves for infants, children and adolescents. In: Proceedings of the 1st National Congress for Egyptian Growth Curves, Cairo University, 11 December 2003. Cairo, Department of Bioanthropology, National Research Centre.

56. **Gilbert GL;(2002).** Infections in pregnant women.; Med J 4;176(5):229-36.

57. **Ginsberg L (2004).** "Difficult and recurrent meningitis". Journal of Neurology, Neurosurgery, and Psychiatry 75 Suppl 1: i16–21.

58. **Gkoltsiou Konstantina , Meropi Tzoufi, Serena Counsell, et al (2008)** . Serial brain MRI and ultrasound findings: Relation to gestational age, bilirubin level, neonatal neurologic status and neurodevelopmental outcome in infants at risk of kernicterus. *Early Human Development* . 11 829-838.

59. **Glascoe, Frances Page et al. (1992).** "Accuracy of the Denver-II in Developmental Screening". *Pediatrics* (89): 1221–1225.

60. **Gonzalez, Jason; Willis, Monte S(2010).** title=Ivar Asbjorn Folling Discovered Phenylketonuria (PKU) - journal=lab medicine - volume=41 - number=2 - pages=118-119

61. **Goodman, S. I.; Markey, S. P.; Moe, P. G et al (1975).** Glutaric aciduria; a 'new' disorder of amino acid metabolism. Biochem. Med. 12: 12-21, 1975.

62. **Guthrie R(1986).** Screening for "inborn errors of metabolism" in the newborn infant—a multiple test program. Birth Defects 4:92-98.

63. **Guthrie R, Susi A(1963).** A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 32:338-343.

64. **Harber JS (1991).** Early diagnosis and referral of children with developmental disabilities, *Am Fam Pract* **43** pp. 132–140.

65. **Hauser WA(1994).** The prevalence and incidence of convulsive disorders in childhood. Epilepsia 35 [Suppl 2]:S1–6.

66. **Hauser WA, Hesdorffer DC (1990).** Epilepsy, Frequency, Causes, and Consequences. New York : Demos,18–21.

67. **Henderson HE, Goodman R, Schram J, Diamond E, et al (1981)** Biochemical screening for inherited metabolic disorders in the mentally retarded. S Afr Med J . 1981; 60: 731–733.

68. **Hirtz D, Thurman DJ, Gwinn-Hardy K, et al (2007).** "How common are the "common" neurologic disorders?". Neurology **68** (5): 326–37.

69. **Illicki A, Larsson A(1988).** Psychomotor development of children with congenital hypothyroidism diagnosed by neonatal screening. *Acta Paediatr Scand* . 77: 142–147.

70. Illingworth RS (1978). Child development. In: Forfar JO, Arneil GC, eds. Textbook of pediatrics. Edinburgh, Scotland: Churchill Livingstone.

71. **James William D.; Berger, Timothy G.; et al. (2006).** Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier.

72. **Jiang Y-H, Lev-Lehman E, Bressler J, et al (1999)** Tsai TF, Beaudet AL. Genetics of Angelman syndrome. Am J Hum Genet. 65 :1 –6.

73. **Johnson JH, Goldman J (1990).** Developmental assessment in clinical child psychology. New York: Pergamon Press .

74. **Johnson LH, Bhutani VK, Brown AK(2002).** System-based approach to management of neonatal jaundice and prevention of kernicterus. J Pediatr. 140(4):396-403.

75. **Jones G, Steketee RW, Black RE, et al(2003).** How many child deaths can we prevent this year? *Lancet* 362:65–71.

76. **Karri, Sk; Saper, Rb; Kales, Sn (Jan 2008).** "Lead encephalopathy due to traditional medicines". *Current drug safety* **3** (1): 54–9.

77. **Knight SJ, Regan R, Nicod A, et al (1999).** Subtle chromosomal rearrangements in children with unexplained mental retardation. *Lancet.* 354 :1676 –1681.

78. **Kodo N, Millington DS, Norwood DL, et al (1992).** Automated analysis of free and short-chain acylcarnitine in plasma with a centrifugal analyzer. Clin Chem 38:2215-2221.

79. **Kolawole TM, Patel PJ, Mahdi AH (1989).** "Computed tomographic (CT) scans in cerebral palsy (CP)". Pediatr Radiol **20** (1–2): 23–7.

80. **Konstantareas MM, Beitchman JH(1991),** eds. Pervasive developmental disorders. Psychiatr Clin North Am 14:1-217

81. **Kosnett, M.J. (2007).** "Heavy metal intoxication and chelators". In Katzung, B.G.. *Basic and Clinical Pharmacology*. McGraw-Hill Professional.

82. **Krauss MJ, Morrissey AE, Winn HN, et al (2003).**Am J Obstet Gynecol 188:1484-90.

83. **Kravetz JD, Federman DG(2005);** Toxoplasmosis in pregnancy. Am J Med. 118(3):212-6.

84. **Kwok SK, Ho PC, Chan AK, et al (1996)** defects in children and adolescents with severe mental deficiency. J Intellect Disabil Res . 40: 330–335.

85. **Kyllerman, M.; Skjeldal, O. H.; Lundberg, et al (1994) :** Dystonia and dyskinesia in glutaric aciduria type I: clinical heterogeneity and therapeutic considerations. Mov. Disord. 9: 22-30,

86. **Laumonnier F, Bonnet-Brilhout F, Gomot M, et al (2004).** X-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family. Am J Med Genet. 74 :552 –557.

87. **Levy SE, Hyman SL (1993).** Pediatric assessment of the child with developmental delay. Pediatr Clin North Am . 1993; 40: 465–477.

88. **Lewis R. First, and Judith S. Palfrey(1994).**The Infant or Young Child with Developmental Delay,Volume 330:478-483.

89. **Lingam S, Read S, Holland IM,et al (1982)**Wilson J, Brett EM, Hoare RD. Value of computerised tomography in children with non-specific mental subnormality. Arch Dis Child. 57 :381 –38.

90. **Lubs HA (1969).** "A marker X chromosome". Am. J. Hum. Genet. **21** (3): 231– 233.

91. **Luckasson RL, Coulter DL, Polloway EA, et al (1992).** Mental retardation: definition, classification and systems of supports. Washington: AAMR.

92. **MacLennan A(1999).** A template for defining a causal relation between acute intrapartum events and cerebral palsy: international consensus statement. *BMJ* 319:1054–1059.

93. **Mahfoud A,Dominguez CL,Rizzo C, Ribes A(2003).** "Rhabdomyolysis in glutaric aciduria type I.". *Rev Neurol* **39** (10): 939–42.

94. **Majnemer A (1998).** Benefits of early intervention for children with developmental disabilities. Semin Pediatr Neurol . 1998; 5: 62–69

95. **Majnemer A, Rosenbaum P, et al(2001)** Etiologic yield of autistic spectrum disorders: a prospective study. J Child Neurol. 16 :509 –512.

96. **Majnemer A, Shevell MI (1995).** Diagnostic yield of the neurologic assessment of the developmentally delayed child. J Pediatr . 127: 193–199

97. **Malm G, Engman ML(2007);** Congenital cytomegalovirus infections. Semin Fetal Neonatal Med. 12(3):154-9.

98. Martin, J. P. & Bell, J (1943). "A pedigree of mental defect showing sex-linkage". Journal of neurology, neurosurgery, and psychiatry (J. Neurol. Psychiat.). BMJ Publishing Group, London 6. , 154-157.

99. **Matsui, Sm; Mahoney, Mj; Rosenberg, Le (1983).** "The natural history of the inherited methylmalonic acidemias" . The New England journal of medicine 308 (15): 857–61.

100. **Mehta NM, Thomas RM(2002);** Antenatal screening for rubella-infection or immunity?; BMJ. 13;325(7355):90-1.

101. **Meisels SJ, Provence S.(1992)** Screening and assessment: guidelines for identifying young disabled and developmentally vulnerable children and their families. Washington, D.C.: National Center for Clinical Infant Programs.

102. **Menacker SJ(1993).** Visual function in children with developmental disabilities. *Pediatr Clin North Am* . 40: 659–674.

103. **Menyuk P(1986).** Predicting speech and language problems with persistent otitis media. In: Kavanagh JF, ed. Otitis media and child development. Parkton, Md.: York Press, 83-96.

104. **Milhorat TH, Bolognese PA, Nishikawa M, et al (2007).** "Syndrome of occipitoatlantoaxial hypermobility, cranial

settling, and chiari malformation type I in patients with hereditary disorders of connective tissue". Journal of Neurosurgery: Spine 7 (6): 601–9.

105. **Minussi L, Mohrdieck R, Bercini M, et al(2008);** Prospective evaluation of pregnant women vaccinated against rubella in southern Brazil. Reprod Toxicol. 25(1):120-3.

106. **Moeschler John B, Michael Shevell(2006),** Clinical Genetic Evaluation of the Child With Mental Retardation or Developmental Delays, PEDIATRICS Vol. 117 No.pp. 2304-2316.

107. **Morton DH, Robinson DL, Puffenberger EG, et al (2003).** "Type I glutaric aciduria, part 1: natural history of 77 patients" . Am J Med Genet C Semin Med Genet **121** (1): 38–52.

108. **Msall ME, Bier JA, LaGasse L,(1998)** Tremont M, Lester B. The vulnerable preschool child: the impact of biomedical and social risks on neurodevelopmental function. *Semin Pediatr Neurol* . 1998; 5: 52–61.

109. **Nayae RL, Peters EC, Bartholomew M, et al (1989).** Origins of cerebral palsy. Am J Dis Child 143:1154–1161.

110. **Needleman HL, ed. Human (1992)** lead exposure. Boca Raton: CRC Press.

111. **Nicholas G. Guerina, Ho-Wen Hsu, et al (1994)** and the New England Regional Toxoplasma Working GroupN Engl J Med ; 330:1858-1863.

112. **Niswander K, Henson G, Elbourne D, et al (1984).**Adverse outcome of pregnancy and the quality of obstetric care.Lancet ;ii:827–31.

113. **Ogier de Baulny H, Saudubray JM (2002).** "Branched-chain organic acidurias". Semin Neonatol. 7 (1): 65–74.

114. **Oswyn G, Vince JD, Friesen H(2000).** Perinatal asphyxia at Port Moresby General Hospital: a study of incidence, risk factors and outcome. *P N G Med J* 43:110–120.

115. **Ozmen M.,Tatli B. and Aydinli N. et al (2005)** Etiologic evaluation in 247 children with global developmental delay at Istanbul Turkey, J Trop Pediatr **51** pp. 310–313.

116. **Palfrey JS (1992).** Legislation for the education of children with disabilities. In: Levine MP, Carey WB, Crocker AC, eds. Developmental-behavioral pediatrics. 2nd ed. Philadelphia: W.B. Saunders, 782-5.

117. **Pharoah PO (2005).** "Causal hypothesis for some congenital anomalies". *Twin Res Hum Genet* **8** (6): 543–50.

118. **Phillips S, Sarles RM, Friedman SB(1992).** Consultation and referral for behavioral and developmental problems. In: Hoekelman RA, Friedman SB, Nelson NM, Seidel HM, eds. Primary pediatric care. 2nd ed. St. Louis: Mosby-Year Book, 678-82.

119. **Pollitt RJ, Green A, McCabe CJ, et al(1997).** Neonatal screening for inborn errors of metabolism: cost, yield and outcome. *Health Technol Assess* . 1: i-iv.

120. **Rapin I(1991).** Autistic children: diagnosis and clinical features. Pediatrics 87:751-760.

121. **Reinecke CJ, Mienie LJ, Hitzeroth HW, et al (1983).** Screening for inborn error of metabolism among mentally retarded patients. Outcome of a survey at the Witrand Care and Rehabilitation Center. *S Afr Med J* . 63: 14–16.

122. **Roschinger W, Olgemoller B, Fingerhut R, et al (2003)** Advances in analytical mass spectrometry to improve screening for inherited metabolic diseases. Eur J Pediatr. 162 (suppl 1):S67–S76.

123. Rosenbaum, RB; DP Ciaverella (2004). Neurology in Clinical Practice. Butterworth Heinemann. pp. 2192–2193.

124. **Rosenberg MJ, Killoran C, Dziadzio L, et al (2001).** Scanning for telomeric deletions **and** duplications and uniparental disomy using genetic markers in 120 children with malformations. *Hum Genet.* 2001;109 :311 –318.

125. **Rupa V(1995).** Dilemmas in auditory assessment of d**evelopmental**ly retarded children using behavioural observation audiometry and brain stem evoked response audiometry. *J Laryngol Otol* . 109: 605–609.

126. **Sáez-Llorens X, McCracken GH (June 2003).** "Bacterial meningitis in children". Lancet 361 (9375): 2139–48.

127. **Saigal S, Szatmari P, Rosenbaum P, et al (1990).** Intellectual and functional status at school entry of children who weighed 1000 grams or less at birth: a regional perspective of births in the 1980's. J Pediatr 116:409-416.

128. **Saudubray J, Sedel F, Walter J (2006).** "Clinical approach to treatable inborn metabolic diseases: an introduction". J Inherit Metab Dis 29 (2-3): 261–74.

129. **Schaefer GB, Bodensteiner JB (1992).** Evaluation of the child with idiopathic mental retardation. Pediatr Clin North Am . 1992; 39: 929–943.

130. **Schaefer GB, Bodensteiner JB(1998).** Radiological findings in developmental delay. Semin Pediatr Neurol. 36 :33 – 38.

131. Schaefer GB, Bodensteiner JB(1998). Radiological findings in developmental delay. Semin Pediatr Neurol. 36 :33 –38

132. **Schmitt B, Seeger J, Kreuz E, et al (1991).** Central nervous system involvement of children with HIV infection. Dev Med Child Neurol 33:535-540.

133. **Shaag, A.; Saada, A ; Berger, I,et al (1999) :** Molecular basis of lipoamide dehydrogenase deficiency in Ashkenazi Jews. Am. J. Med. Genet.82:177-182.

134. **Shalowitz MU, Gorski PA (1990).** Developmental assessment in the first year of life. In: Stockman JA III, ed. Difficult diagnosis in pediatrics. Philadelphia: W.B. Saunders, 3-14.

135. **Sherman, S. (2002).** "Epidemiology". Chapter 3 in Fragile X Syndrome, Diagnosis Treatment and Research. Ed. Hagerman, R. J. & Hagerman, P.J. (3rd Edition). Johns Hopkins University Press: Baltimore.

136. **Shevell M MD, CM, FRCPC (2008).** Global Developmental Delay and Mental Retardation or Intellectual Disability: Conceptualization, Evaluation, and Etiology Pediatric Clinics of North AmericaVolume 55, Issue 5, Developmental Disabilities, Part I Pages 1071-1084.

137. **Shevell M, Ashwal S, Donley D, et al (2003).** Practice parameter: Evaluation of the child with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 60 :367 –380.

138. Shevell M.I. and Sherr E. (2006)., Global developmental delay and mental retardation. In: K. Swaiman, S. Ashwal and D.

Ferreiro, Editors, *Pediatric Neurology: Principles & Practice* ((ed 4).), Mosby Elsevier, Philadelphia, PA pp. 799–820.

139. Shevell M. MD, CM, FRCPC (2006). Office evaluation of the child with developmental delay, Practical Office Management of Common Pediatric Neurology Problems Volume 13, Issue 4, Pages 256-261**,**

140. **Shevell M.I., Majnemer A. and Morin I.,(2003)** Etiologic yield of cerebral palsy: A contemporary case-series, Pediatr Neurol **28** , pp. 352–359.

141. **Shevell M.I., Majnemer A. and Rosenbaum P. *et al.*,(2001)** Etiologic yield of autistic spectrum disorders: A prospective study, J Child Neurol **16** (2001), pp. 509–512.

142. **Shevell M.I., Ashwal S. and Donley D. et al.,(2003)** Practice parameter: Evaluation of the child with global developmental delay, Neurology **60** (2003), pp. 367–379.

143. **Shevell M.I., Majnemer A. and Rosenbaum P. et al.,(2000)** Etiologic yield in single domain developmental delay: A prospective study, J Pediatr **137** (2000), pp. 633–637.

144. **Shevell MI (1998).** The evaluation of the child with a global developmental delay. Semin Pediatr Neurol . 1998; 5: 21–25.

145. **Shevell MI, Majnemer A, Rosenbaum P, Abrahamowicz M(2001).** Etiologic yield of autistic spectrum disorders: a prospective study. *J Child Neurol.* 16 :509 –512.

146. **Shevell MI, Majnemer A, Rosenbaum P, et al (2000)** Etiologic yield of subspecialists' evaluation of young children with global developmental delay. J Pediatr. 136 :593 –598.

147. **Shevell MI, Majnemer A, Rosenbaum P, et al (2001)** Etiologic determination of childhood developmental delay. Brain

Dev. 2001;23 :228 –235.

148. **Shonkoff JP, Hauser-Cram P(1987).** Early intervention for disabled infants and their families: a quantitative analysis. Pediatrics 80:650-658.

149. **Simeonsson RJ, Sharp MC (1992).** Developmental delays. In: Hoekelman RA, Friedman SB, Nelson NM, et al., eds. Primary pediatric care. St. Louis: Mosby-Year Book, 867–870.

150. **Slavotinek A, Rosenberg M, Knight S, et al (1999).** Screening for submicroscopic chromosome rearrangements in children with idiopathic mental retardation using microsatellite markers for the chromosome telomeres. J Med Genet. 36 :405 – 411.

151. **Srour M., Mazer B. and M.I. Shevell M.I., (2006)** Analysis of clinical features predicting etiologic yield in the assessment of global developmental delay, Pediatrics **118** , pp. 139–145.

152. **Straus SE, Thorpe KE, Holroyd-Leduc J (2006).** "How do I perform a lumbar puncture and analyze the results to diagnose bacterial meningitis?". JAMA : the journal of the American Medical Association **296** (16): 2012–22.

153. **Szabó, Nóra; Pap, Csenge; Kóbor, Jenő; et al (2010).** LászlóActa Pædiatrica, Volume 99, Number 5, pp. 690-693.

154. **Tarim OF, Yordam N(1992).** Congenital hypothyroidism in Turkey: a retrospective evaluation of 1000 cases. *Turk J Pediatr* . 34: 197–202.

155. **Thompson MGG(1990).** Developmental assessment of the preschool child. In: Stockman JA III, ed. Difficult diagnosis in pediatrics. Philadelphia: W.B. Saunders, 15-28.

156. **Thorngren-Jerneck K, Herbst A (2006).** "Perinatal factors associated with cerebral palsy in children born in Sweden". Obstetrics and gynecology **108** (6): 1499–505.

157. **Timbrell, J.A., ed (2008).** "Biochemical mechanisms of toxicity: Specific examples". Principles of Biochemical Toxicology, 4th edition. Informa Health Care.

158. **Tjio J.H & Levan A (1956).** The chromosome number of man. *Hereditas* 42, 1-6. .

159. **Tortorelli, S.; Hahn, S. H.; Cowan, et al (2005):** The urinary excretion of glutarylcarnitine is an informative tool in the biochemical diagnosis of glutaric acidemia type I. Molec. Genet. Metab. 84: 137-143.

160. **Tunkel AR, Hartman BJ, Kaplan SL (2004).** "Practice guidelines for the management of bacterial meningitis". Clinical Infectious Diseases 39 (9): 1267–84.

161. **Van Karnebeek CD, Jansweijer MC, Leenders AG, et al (2005).** Diagnostic investigations in individuals with mental retardation: a systematic literature review of their usefulness. Eur J Hum Genet. 13 :6 –25.

162. van Karnebeek CD, Jansweijer MC, Leenders AG, et al (2005). Diagnostic investigations in individuals with mental retardation: a systematic literature review of their usefulness. *Eur J Hum Genet.*13 :6 –25.

163. **Van Karnebeek CD, Koevoets C, Sluijter S, et al (2002).** Prospective screening for subtelomeric rearrangements in children with mental retardation of unknown aetiology: the Amsterdam experience. J Med Genet. 39 :546 –553.

164. **Van Karnebeek CDM, Scheper FY, Abeling NG, et al (2002).**Amsterdam, Netherlands: Department of Pediatrics/Emma Children's Hospital and Department of Clinical Genetics, Academic Medical Centre, University of Amsterdam; 75 –108.

165. **Walker D, Gugenheim S, Downs MP, et al (1989).** Early Language Milestone Scale and language screening of young children. Pediatrics 83:284-288.

166. **Warburg M(1994).** Visual impairment among people with developmental delay. *J Intellect Disabil Res* . 38: 423–432.

167. **Wendy S Meschino, MD FRCPC FCCMG (2003).** Department of Genetics, North York General Hospital, Toronto, OntarioCorrespondence: Dr Wendy S Meschino, Clinical Geneticist, Department of Genetics, North York General Hospital.

168. **White BJ, Ayad M, Fraser A, et al (1999).** A 6-year experience demonstrates the utility of screening for both cytogenetic and FMR-1 abnormalities in patients with mental retardation. Genet Test . 3: 291–296.

169. **Willi SM, Moshang Jr T(1991).** Results of screening tests for congenital hypothyroidism. *Pediatr Clin North Am* . 38: 555–566.

170. **Yaqub BA(1996).** Subacute sclerosing panencephalities (SSPE): early diagnosis, prognostic factors and natural history. *J Neurol Sci* 139: 227–234.

171. **Yeargin-Allsopp M, Murphy CC, Cordero JF, et al (1997).** Reported biomedical causes and associated medical conditions for mental retardation among 10 year old children, metropolitan Atlanta, 1985 to 1987. Dev Med Child Neurol . 39: 142–149.

172. **Yeum CH, Kim SW, Kim NH, Choi KC, Lee J (2002).** "Increased expression of aquaporin water channels in hypothyroid rat kidney". Pharmacol. Res. **46** (1): 85–88.

173. **Zarmeneh Aly, Fawad Taj, and Shahnaz Ibrahim (2010).**brain and development Volume 32, Issue 2, Pages 90-97

174. **Zoghbi HY (2003).** Postnatal neurodevelopmental disorders: meeting at the synapse? Science. 302 :826 –830.

175. **Zuckerman B, Bresnahan K (1991).** Developmental and behavioral consequences of prenatal drug and alcohol exposure. Pediatr Clin North Am 38:1387-1406.